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Abstract  Idiopathic  pulmonary  ﬁbrosis  is  a  rare  interstitial  lung  disease  included  in  the
Idiopathic  Interstitial  Pneumonias  group.  Although  several  potential  risk  factors  have  been
described, it  is  a  progressive  ﬁbrosing  disease  of  unknown  cause  affecting  mainly  adults  over
50 years  and  associated  with  a  poor  prognosis,  reﬂected  in  a  median  survival  of  2--3  years  after
diagnosis.
The concept  of  a  multidisciplinary  working  group  for  the  diagnosis  of  idiopathic  pulmonary
ﬁbrosis is  based  on  the  need  to  have  experienced  pulmonologists,  radiologists  and  pathologists
in the  evaluation  and  correct  treatment  of  the  disease,  and  requires  the  use  of  all  availablents,  standardized  (largely  through  High  Resolution  Computed  Tomo-
n  needed)  as  well  as  non-standardized  data  (laboratory,  serology
oach  helps  to  increase  diagnostic  accuracy  and  is  an  internationallydata about  individual  patie
graphy and  pathology  whe
and biomarkers).  This  appr
accepted  recommendation.
∗ Corresponding author.
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173-5115/© 2016 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC
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In  regard  to  therapy,  the  situation  has  changed  radically  since  the  publication  of  the
ATS/ERS/JRS/ALAT  2011  guidelines  on  the  diagnosis  and  management  of  idiopathic  pulmonary
ﬁbrosis where  it  was  stressed  that  no  proven  therapy  exists  for  this  disease.
Currently  besides  non-pharmacological  treatment,  therapy  of  complications  and  comor-
bidities  and  palliative  care,  nintedanib  and  pirfenidone,  two  compounds  with  pleiotropic
mechanisms  of  action,  are  to  date,  the  two  drugs  with  conﬁrmed  efﬁcacy  in  slowing  functional
decline and  disease  progression  in  idiopathic  pulmonary  ﬁbrosis  patients.
© 2016  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,
S.L.U. This  is  an  open  access  article  under  the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
w
t
f
g
(TERT  --  Telomerase  reverse  transcriptase,  TERC  --  Telom-
erase  RNA  component),  mutations  in  the  surfactant  protein
C  gene  and  mutations  in  the  mucin  5B  promoter  region
(MUC5B)20--23;  (c)  gastro-oesophageal  reﬂux  (GER),  consid-
Table  1  Idiopathic  pulmonary  ﬁbrosis  diagnosis  exami-
nations.
At  IPF  diagnosis
Systematic
Chest  HRCT
Plethysmography  and  DLCO
Arterial  blood  gas  in  room  air  at  rest
6MWT  with  measurement  of  percutaneous  oxygen
saturation
Doppler  echocardiography
Biology
Antinuclear  antibodies
Anti-citrullinated  cyclic  peptides  antibodies
Rheumatoid  factor
Extractable  Nuclear  Antigens  antibodies
Occasional
Video-assisted  surgical  lung  biopsy
Differential  cell  count  of  BAL
Depending  on  context
Genetic  testing
Anti-neutrophil  cytoplasmic  antibodies
Creatine  phosphokinase
Anti-thyroid  antibodies
Precipitins  (depending  on  disease  presentation)
Electrophoresis  of  serum  proteins,
immuno-electrophoresis  of  serum  proteins,  urine
immunoﬁxation  and  cryoglobulinaemia
Exploration  for  gastro-oesophageal  reﬂux
Exploration  for  sleep  apnoea  syndromeIntroduction
Idiopathic  pulmonary  ﬁbrosis  (IPF)  is  the  most  common  and
fatal  of  the  idiopathic  interstitial  pneumonias  subgroup.1--5
After  the  ﬁrst  IPF  consensus6 of  the  American  Thoracic
Society  (ATS)/European  Respiratory  Society  (ERS)  in  2000,
several  studies  contributed  to  a  greater  knowledge  of  IPF
diagnosis  and  treatment,  which  was  reﬂected  in  the  updated
international  consensus  on  the  diagnosis  and  management
of  IPF  published  in  2011  and  signed  by  the  American  (ATS),
European  (ERS),  Japanese  (JRS)  and  Latin  American  Associa-
tions  (ALAT).1 Since  this  publication  several  developments  in
the  IPF  management  there  have  been,  including  diagnostic
criteria  and  therapeutic  options.7--11
Interstitial  lung  diseases  are  identiﬁed  as  priority  inter-
vention  in  the  Portuguese  National  Program  of  Respiratory
Diseases12;  nonetheless  there  is  a  general  consensus  about
the  need  for  greater  awareness  for  the  identiﬁcation  of
these  patients,  enabling  an  earlier  diagnosis  and  treatment.
Deﬁnition
IPF  is  deﬁned  as  a  speciﬁc  form  of  chronic,  progressive
ﬁbrosing  interstitial  pneumonia  of  unknown  cause,  predom-
inantly  in  adults  over  50  years,  limited  to  the  lungs,  and
associated  with  the  radiologic  and/or  histopathologic  pat-
tern  of  usual  interstitial  pneumonia  (UIP).1--3,13
Epidemiology
Depending  on  the  criteria  and  methodology  adopted  in  reli-
able  studies,14 IPF  incidence  ranges  between  0.22  and  17.4
per  100,000  person-year,  and  the  prevalence  between  14  and
27.9  cases  per  100,000  persons.  It  is  unknown  if  geographic,
ethnic,  cultural  or  racial  factors  inﬂuence  the  incidence  and
prevalence  of  IPF.1,15 IPF  is  associated  with  a  poor  prognosis,
with  a  median  survival  of  2--3  years  after  the  diagnosis.16--18
Risk factorsAlthough  the  aetiology  of  IPF  is  unknown,  several
potential  risk  factors  have  been  identiﬁed  including:
(a)  environmental  factors  like  smoking  history  of  >20
packs/year,  exposure  to  silicon,  brass,  steel,  lead  andood  dust,  farming  and  agricultural  work,  construc-
ion  of  wooden  houses19; (b)  genetic  factors  such  as
amilial  pulmonary  ﬁbrosis,  mutations  in  the
enes  that  maintain  the  length  of  the  telomeresAdapted from Cottin et al.3
6MWT: 6-min walk test; BAL: bronchoalveolar lavage; DLCO:
diffusing capacity of the lung for carbon monoxide; HRCT: high-
resolution computed tomography.
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red  a  risk  factor  for  the  predisposition  and  progression
f  IPF24,25;  (d)  viral  infections,  although  there  is  no  suf-
cient  data  to  state  their  role  in  IPF  despite  the  large
umber  of  studies  analyzing  the  etiological  risk  effect  of
epatitis  C  virus,  herpes  virus  and  adenovirus26,27;  and  (e)
utoimmunity,  that  is  still  being  studied  but  the  possible
utoimmune  origin  of  IPF  is  based  on  the  association  of
adiologic  and/or  histologic  manifestations  of  UIP  to
onnective  tissue  diseases.1,13
iagnosis
he  diagnosis  of  IPF  requires  a  multidisciplinary  approach,
ncluding  the  awareness  of  general  practice  physicians,  and
xperienced  pulmonologists,  radiologists  and  pathologists  in
he  evaluation  and  correct  treatment  of  diffuse  interstitial
ung  disease  (DILD).1,3,13,28--31 This  approach  helps  increase
iagnostic  accuracy  and  is  an  internationally  accepted
ecommendation.28,29
Table  1  presents  the  procedures  that  should  be  performed
t  diagnosis,  systematically  and  occasionally.
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dyspnea on  exertion
non-productive cough
age > 50 years
smoking habits
crackles on auscultation
digital clubbing
IPF
IPF
HRTC
Laboratory exams
Serological tests
Biomarkers
Exclusion of other ILD
and clear UIP pattern
Exclusion
and possib
B
IPF SUSPECTED
Presence of:
igure  1  IPF  diagnosis  algorithm.  ILD:  interstitial  lung  disease;  IPF:
omography;  UIP:  usual  interstitial  pneumonia.C.  Robalo  Cordeiro  et  al.
The  general  practice  physician  must  be  aware  of  IPF
ymptoms  in  order  to  consider  this  disease  when  establish-
ng  the  initial  diagnosis,  and  to  refer  IPF  suspicious  cases  to
 pulmonologist.
The diagnosis  of  IPF  requires  the  exclusion  of  other  known
auses  of  interstitial  lung  disease  (domestic  or  occupa-
ional  environmental  exposures,  connective  tissue  disease,
rug  toxicity)  and  the  presence  of  a typical  histological  UIP
attern.1,3,7,13,18,32 According  to  the  ATS/ERS  recommenda-
ions  and  validated  by  international  societies,  in  the  absence
f  biopsy,  IPF  can  be  diagnosed  only  based  on  radiologi-
al  criteria  from  the  high  resolution  computed  tomography
HRCT).1
Fig.  1  presents  the  algorithm  proposed  for  the  diagnosis
f  IPF.  In  case  of  IPF  suspicion,  all  the  possible  associ-
tions  with  UIP  radiological  pattern  must  be  accurately
nvestigated.  Since  UIP  pattern  can  be  associated  with
everal  autoimmune  diseases,  such  as  rheumatoid  arthritis,
ystemic  sclerosis  or  Sjögren  syndrome  or  even,  although
arely,  with  ANCA-positive  vasculitis,  all  patients  should
erform  serological  autoimmune  tests,  although  positive
nti-nuclear  antibodies  or  rheumatoid  factor  can  be
Not IPF
Not UIP pattern
Not IPF
Other ILD
Not IPF
 of other ILD
le UIP pattern
iopsy
 idiopathic  pulmonary  ﬁbrosis;  HRCT:  high-resolution  computed
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Table  2  High-resolution  computed  tomography’s  idiopathic  pulmonary  ﬁbrosis/usual  interstitial  pneumonia  diagnosis  criteria.
UIP  pattern  (all  of  the  following)  Possible  UIP  pattern  (all  of  the
following)
UIP-IPF  pattern  (1  +  2)
1-Subpleural,  basal  (predominant
distribution)
1-Subpleural,  basal
(predominant  distribution)
1-All  of  UIP  pattern
2-Reticulation  2-Reticulation  2-Absence  of  ﬁndings  that  do
not  support  a  UIP  pattern
3-Honeycombing  with  or  without  traction
bronchiectasis
3-Absence  of  ﬁndings  that  do
not  support  a  UIP  pattern
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The  histological  pattern  of  UIP  must  present:  1  --
marked  ﬁbrosis/architectural  distortion,  with  or  without
honeycombing  in  a predominantly  subpleural/paraseptal
distribution;  2  --  patchy  involvement  of  lung  parenchyma  by
Table  3  Inconsistent  criteria  in  the  high-resolution  com-
puted tomography’s  idiopathic  pulmonary  ﬁbrosis/usual
interstitial  pneumonia  diagnosis.
Any  of  the  following
Predominance  of  middle  or  upper  distribution
Peri-bronchovascular  distribution
Reticular  ground  glass  opacities
Micronodules  (bilateral  and  upper  lobes  predominance)
Axial cysts  (multiple,  bilateral,  distant  from  the  areas  of
honeycombing)
Mosaic  pattern,  diffuse/air  trapping  (bilateral,  in  threeAdapted from Raghu et al.1
IPF: idiopathic pulmonary ﬁbrosis; UIP: usual interstitial pneumon
detected  in  up  to  20%  of  IPF  cases  as  an  unspeciﬁc  feature
with  no  association  with  any  particular  disorder.1,32--34 The
presence  of  serum  speciﬁc  IgG  against  the  antigens  that
can  frequently  cause  hypersensitivity  pneumonitis  should
also  be  systematically  assessed.1,30,34,35
Bronchoalveolar  lavage  (BAL)  is  not  included  in  this
algorithm  as  a  diagnostic  procedure  since  it  is  not  rec-
ommended  that  BAL  be  systematically  performed  in  all
patients,  although  it  may  be  appropriate  for  a  minority  of
cases.3,36--39 Nevertheless,  Centres  with  experience  in  this
approach  might  use  BAL  regularly  as  it  can  either  rule  out
or  help  diagnose  IPF,  especially  when  a  higher  lymphocyto-
sis  guides  the  diagnosis  for  other  entities,  as  for  instance
hypersensitivity  pneumonitis.37 On  the  other  hand,  the  use
of  transbronchial  biopsy  in  the  diagnosis  of  IPF  is  controver-
sial.  Cryobiopsy,  although  it  is  not  yet  widely  used  and  must
only  be  performed  in  Centres  with  experience  in  this  pro-
cedure,  the  published  data  so  far  shows  that  cryobiopsy  in
ﬁbrotic  ILDs  yields  large  and  well-preserved  lung  specimens,
sufﬁcient  to  enclose  all  the  UIP  characteristic  features,  with
safety  and  tolerability.40--42 In  a  recent  cross-sectional  study,
a  comparison  of  cryobiopsies  with  surgical  lung  biopsies
in  ﬁbrotic  ILD  by  a  multidisciplinary  committee,  conclude
a  major  increase  in  diagnostic  conﬁdence  after  the  addi-
tion  of  cryobiopsies  similar  to  surgical  lung  biopsy  (SLB)  in
IPF  diagnosis  (from  29%  to  63%,  p  =  0.0003  and  from  30%
to  65%,  p  =  0.0016  of  high  conﬁdence  in  the  bronchoscopic
lung  cryobiopsy  group  and  SLB  group  respectively),  which
constitutes  robust  evidence  of  the  potential  role  of  this
bronchologic  procedure.43
High  resolution  computed  tomography
The  purpose  of  HRCT  is  to  identify  the  typical  pattern  of
changes  of  UIP  (Table  2)  or  other  patterns  that  may  be
present,  supporting  the  diagnosis  of  other  lung  diseases.
To  standardize  these  radiological  criteria,  the  report  should
use  descriptive  concepts  based  on  the  terminology  recom-
mended  by  Fleischner  Society.44
The  identiﬁcation  of  lung  honeycombing  is  crucial  for  the
diagnosis  of  IPF  --  they  are  cystic  axial,  conﬂuent  or  lay-
ered  images,  with  diameters  of  3--10  mm,  reaching  2.5  cm.
The  distribution  is  usually  subpleural  or  in  the  reticulation
areas.45--49
There  are  two  aspects  that  may  raise  doubts  in  the  HRTC
interpretation:  the  distinction  between  honeycombing  and
traction  bronchiolectasis  and  ﬁbrosis  with  emphysema.  Theifferential  diagnosis  is  a  challenge  even  for  an  experienced
adiologist.47,49,50 The  2011  ATS/ERS/JRS/ALAT  multidisci-
linary  consensus1 stated  that  the  identiﬁcation  of  four
ypical  ﬁndings  establishes  the  deﬁnite  diagnosis  of  UIP:
 --  subpleural  and  basal  lung  lesions  predominance;  2
- reticulation;  3  --  honeycombing  with/without  traction
ronchiectasis/bronchiolectasis;  4  --  absence  of  ﬁndings  that
o  not  support  a  UIP  pattern  (Tables  2  and  3;  Fig.  2).
The  HRCT  positive  predictive  value  in  the  diagnosis  of
IP  is  90--100%.  The  histopathology  may  also  establish  a  UIP
iagnosis  in  patients  with  no  UIP  lesions  in  the  HRTC.
The  2011  ofﬁcial  ATS/ERS/JRS/ALAT  consensus  estab-
ished  the  use  of  ‘‘deﬁnitive’’  and  ‘‘possible’’  IPF;  these  def-
nitions  simplify  the  deﬁnitive  diagnosis  except  for  the  other
atients.  According  with  to  this  multidisciplinary  consensus,
he  diagnosis  of  UIP/IPF  must  be  based  on  the  consensus
etween  the  clinician,  the  radiologist  and  the  pathologist.1
istopathology
 surgical  lung  biopsy  should  establish  the  diagnosis  of  IPF
f  there  are  doubts  about  the  presence  of  a  deﬁnitive  UIP
ypical  pattern  in  the  HRCT  interpretation.  In  patients  with
uspected  IPF,  surgical  lung  biopsies  should  be  obtained  from
ultiple  lobes,  avoiding  the  extremity  of  the  lingula  and
iddle  lobe.1,51or more  lobes)
Segment  consolidation/lobar
Adapted from Raghu et al.1
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brosis;  3  --  ﬁbroblast  foci;  4  --  absence  of  features  against  a
iagnosis  of  UIP  suggesting  an  alternate  diagnosis1,51 (Fig.  2).
In  some  diseases,  like  rheumatoid  arthritis,  chronic
ypersensitivity  pneumonitis  or  drug-induced  pneumonitis,
sbestosis  and  familial  ﬁbrosis,  a  histological  pattern
ndistinguishable  from  UIP  can  be  observed,  so  the  presence
f  granulomas,  asbestos  bodies,  speciﬁc  infections  or  other
xogenous  agents  must  be  discarded  in  the  biopsy.13,51
The  biopsy  should  only  be  performed  after  a  multidis-
iplinary  meeting  where  IPF  diagnosis  was  not  deﬁned  by
RCT;  if  the  biopsy  is  performed,  its  results  should  again  be
iscussed  in  a  multidisciplinary  meeting.51
ollow-upt  is  recommended  that  IPF  patients  perform  a  follow-up
linic  visit  every  3--6  months.  Table  4  presents  the  main
xaminations  that  are  useful  for  IPF  management.
a
p
p
igure  2  UIP/IPF  identiﬁcation  in  HRCT  and  histopathology.  Case  1
n honeycombing  as  a  result  of  subpleural  airway  spaces  conﬂuence  
redominant.  HE  100×. Case  1  --  b:  The  previous  image  aspects  ar
ormed subpleural  smaller  conﬂuent  airspaces.  HE  100×. Case  1  --  
bres and  is  represented  by  fusiform  cells,  either  ﬁbroblasts  or  mio
ase 2  --  a:  Irregular  conﬂuent  air  spaces  with  typical  subpleural  local
y fusiform  cells.  HE  100×.  Case  2  --  b:  The  adjacent  lobular  paren
verinﬂation and  pseudo  emphysema  morphology.  HE  100×. Case  2  -
nlarging alveoli  septae  till  central  bronchiolo-vascular  axes  and  al
onﬂuent air-spaces  with  bronchial-like  epithelium  and  juvenile  fo
00×. Case  3  --  b:  UIP/IPF  heterogeneous  morphology  in  airspaces  c
hole lobule.  HE  100×.C.  Robalo  Cordeiro  et  al.
atient ﬂow
etting  an  IPF  patient  ﬂow,  which  deﬁnes  the  several  steps
rom  diagnosis  to  treatment,  may  represent  the  identiﬁca-
ion  of  more  cases  of  IPF,  in  a  shorter  period  of  time  and  in
arly  stages  of  the  disease  (Fig.  3).
harmacological treatment
he  therapeutic  strategy  in  IPF  should  be  individualized
or  each  patient,  considering  the  evaluation  of  poten-
ial  beneﬁts  and  risks.  It  is  more  important  to  take  into
ccount  the  clinical  behaviour  than  the  respiratory  function
arameters.52
Nintedanib  and  pirfenidone,  two  compounds  with
leiotropic  mechanisms  of  action  are,  to  date,  the  two  drugs
 --  a:  Common  histopathological  features  of  UIP/IPF  consisting
with  bronchialization  of  epithelium  where  mucus  cells  may  be
e  revealed  by  higher  production  of  mucus  occupying  the  new
c:  The  interstitium  intermingling  honey-combing  loses  elastin
ﬁbroblasts,  with  collagen  deposition.  Elastin-van  Gieson  100×.
ization  of  UIP/IPF  honeycombing  with  interstitium  enlargement
chyma  accentuate  histopathological  heterogeneity,  starting  by
-  c:  The  lobular  histopathological  remodelling  aspect  of  ﬁbrosis
veolar  bronchialization.  HE  100×. Case  3  --  a:  Small  subpeural
ci  of  ﬁbroblasts  in  myxoid  matrix;  lymphocytes  are  seen.  PAS
onﬂuence  with  subpleural  preponderance  and  committing  the
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rFigure  2  
with  conﬁrmed  efﬁcacy  in  slowing  functional  decline  and
disease  progression  in  IPF  patients.7,53,54
Nintedanib
Nintedanib  is  a  tyrosine  kinase  inhibitor  small  molecule
that  targets  receptors  of  growth  factors,  speciﬁcally  inhibits
platelet-derived  growth  factor  receptor  (PDGFR),  ﬁbroblasts
growth  factor  receptor  (FGFR)  and  vascular  endothelial
growth  factor  receptor  (VEGFR),55--57 involved  in  the  lung
ﬁbrosis  mechanism.  It  is  believed  that  nintedanib  reduces
the  progression  of  the  disease  and  the  decline  in  lung
r
b
a
pntinued  )
unction  by  blocking  the  signalling  pathways  involved  in  the
brotic  processes.55--57
The  TOMORROW  Phase  II  trial  showed  that  nintedanib,
50  mg  twice  daily,  was  effective  in  reducing  forced  vital
apacity  (FVC)  decline,  in  preventing  acute  exacerbations,
nd  preserving  health-related  quality  of  life  (HRQoL).9 The
hase  III  INPULSIS-1  and  INPULSIS-2  trials,  showed  that
intedanib  slowed  disease  progression,  reducing  the  annual
ate  of  lung  function  decline  of  50%.11 It  also  presented  a  68%
eduction  of  adjudicated  acute  exacerbations,11 which  can
e  crucial  since  approximately  50%  of  IPF  acute  exacerbation
dmitted  patients  die  during  hospitalization.58 After  the  ﬁrst
ublication  further  subgroup  analysis  of  pooled  data  from
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Table  4  Idiopathic  pulmonary  ﬁbrosis  management  exami-
nations.
During  IPF  follow-up
Every  6  months
FVC  and  DLCO
Arterial  blood  gas  in  room  air
6MWT
Chest  X  ray
Depending  on  context
Chest  HRCT
Doppler  echocardiography
TLC
Right  heart  catheterization
Adapted from Cottin et al.3
6MWT: 6-min walk test; DLCO: diffusing capacity of the lung
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General practice ph ysicians:
Disease and symptoms
awarenes s
Chest X-ray
HRCT
Pulmonologist:
Further study to exclude
other hypothesis
Respirator y function tests
Laborator y exams
Serological tests
Biomarkers
Specialized pulmonologist
and multidisciplinary team:
Definitive diagnosis
Treatment advice
Pulmonologist:
Follow-up
Specialized pulmonologist
and multidisciplinary team:
Frequent follo w-up visit
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cfor carbon monoxide; FVC: forced vital capacity; HRCT: high-
resolution computed tomography; TLC: total lung capacity.
he  INPULSIS  trials  demonstrated  that  nintedanib  slowed  dis-
ase  progression  by  reducing  the  annual  rate  of  FVC  decline
ndependently  of  the  FVC  value  (FVC  >80%  versus  <80%  or
VC  >70%  versus  <70%),  of  the  presence  of  emphysema  at
aseline,  of  the  presence  of  honeycombing  and/or  biopsy
onﬁrmation  of  UIP  or  in  the  absence  of  both,  namely  the
resence  of  ‘‘possible  UIP’’  on  HRCT  scan  without  histology
onﬁrmation.
Although  these  studies  were  not  dimensioned  to  detect
tatistical  differences  in  mortality,  the  pooled  analysis  of
ata  from  the  TOMORROW  and  INPULSIS  trials  shows  a  trend
owards  reduction  in  mortality,  since  after  52  weeks  the  pro-
ortion  of  patients  who  died  from  any  cause  was  5.8%  in  the
intendanib  arm  and  8.3%  in  the  placebo  group  (HR  0.70  [95%
I:  0.46,  1.08];  p  =  0.0955).  Respiratory  mortality  was  also
omparatively  low  in  the  nintendanib  arm  (3.6%  versus  5.7%
-  HR  0.62  [95%  CI:  0.37,  1.06];  p  =  0.0779).11,59
The  most  frequent  adverse  events  during  these  trials
ere  diarrhoea,  nausea  and  vomiting,  that  can  be  easily
anaged  in  most  patients.11
Nintedanib  is  approved  in  the  US  and  EU  for  the  treat-
ent  of  IPF  patients,  regardless  of  disease  severity,  under
he  brand  name  OFEV®.
irfenidone
irfenidone  is  a  pyridine  compound  with  antiﬁbrotic  and
nti-inﬂammatory  properties,  indicated  for  the  treatment
f  mild  to  moderate  IPF.60 The  mechanism  of  action  of  pir-
enidone  has  not  been  fully  established,  but  it  is  known
hat  pirfenidone  attenuates  ﬁbroblast  proliferation,  produc-
ion  of  ﬁbrosis-associated  proteins  and  cytokines,  and  the
ncreased  biosynthesis  and  accumulation  of  extracellular
atrix  in  response  to  cytokine  growth  factors  such  as  trans-
orming  growth  factor-beta  (TGF-) and  platelet-derived
rowth  factor  (PDGF).60
Despite  the  conﬂicting  outcomes  related  to  FVC  decline
8n  the  CAPACITY  trials  004  and  006,  the  pooled  data showed
 pirfenidone  treatment  effect  in  percentage  predicted
VC  at  week  72  with  a  dose  of  2403  mg/day  (−8.5%  ver-
us  −11.0%;  p  =  0.005)  and  a  smaller  proportion  of  patients
f
(
iigure  3  Idiopathic  pulmonary  ﬁbrosis  patient  ﬂow.  HRCT:
igh-resolution  computed  tomography.
ith  a  FVC  decline  ≥10%.  Pirfenidone  also  prolonged  pro-
ression  free  survival  by  23%  when  compared  with  placebo.8
 31%  relative  difference  favouring  pirfenidone8 was  noted
elated  to  6-min  walk  test  (6MWT)  also  at  week  72.  The  pos-
erior  phase  III  ASCEND  trial  showed  a  reduction  of  47.9%
f  patients  with  a  FVC  percentage  predicted  value  decline
10%  or  who  died.10 There  was  also  an  increase  of  132.5%  in
roportion  of  patients  with  no  decline  in  FVC  (p  < 0.001).10
 reduced  decline  in  6MWT  (p  =  0.04)  and  an  improved  pro-
ression  free  survival  (p  <  0.001)  were  also  noted.10
Moreover,  in  a  pooled  analysis  enclosing  CAPACITY  and
SCEND  trials,  there  was  a  signiﬁcant  difference  in  death
ases  from  any  causes  between  patients  treated  with  pir-
enidone  and  placebo  (p  =  0.01)  and  death  related  with  IPF
p  =  0.006).10
In  a  recent  pooled  data  analysis  of  outcomes  at  1  year
n  CAPACITY  and  ASCEND  trials  including  a total  of  1247
s
r
T
A
H
s
s
f
s
G
A
n
t
t
n
i
b
P
P
I
p
d
8
S
t
w
e
f
d
s
r
d
i
d
t
t
I
d
a
i
i
c
t
P
TConsensus  document  for  the  diagnosis  and  treatment  of  IPF  
patients  pirfenidone  reduced  the  proportion  of  patients  with
a  ≥10%  decline  in  FVC  percentage  or  death  by  43.8%  (95%  CI
29.3--55.4%)  and  increased  the  proportion  of  patients  with
no  decline  by  59.3%  (95%  CI  29.0--96.8%).  Progression  free
survival,  6MWT  and  dyspnoea  also  showed  a  positive  impact
from  pirfenidone.  These  results  provided  further  evidence
about  the  beneﬁt  of  pirfenidone  in  IPF  disease  progression.61
The  most  common  adverse  events  during  these  tri-
als  were  photosensibility,  gastro-intestinal  occurrences  and
gastro-oesophageal  reﬂux,  generally  reversible  with  dose
reductions.8,10,62--64
Pirfenidone  is  approved  for  the  treatment  of  mild  to  mod-
erate  IPF  patients,  under  the  brand  name  of  Esbriet®.
Although  some  data  is  available  related  with  the  concom-
itant  therapy  with  nintedanib  and  pirfenidone,  this  approach
cannot  be  recommended  since  its  efﬁcacy  and  tolerability
is  not  sufﬁciently  evidenced.65
Other  drugs
After  the  IFIGENIA  study,66 N-acetylcysteine  (NAC)  combined
with  prednisone  and  azathioprine  was  the  treatment  of
choice  for  several  years.1 With  the  presentation  of  the  sub-
sequent  PANTHER  study,67 which  showed  higher  mortality
and  hospital  admissions  in  patients  receiving  NAC  combi-
nation  therapy  compared  to  placebo  or  NAC  alone,  the
triple  therapy  is  not  recommended.1 Additionally,  NAC  as
monotherapy  did  not  show  efﬁcacy  versus  placebo.68
Various  compounds,  including  anti-coagulants,  interferon
gamma-1b,  anti-acids,  anti-inﬂammatory  and  vasodilator
agents25,40,69--81 have  been  tested  in  IPF  patients  but  have
not  demonstrated  deﬁnitive  efﬁcacy  for  the  treatment  of
IPF.  In  addition,  there  are  currently  several  ongoing  clinical
trials  results  of  which  will  be  available  in  the  near  future.
Non-pharmacological treatment
Respiratory  rehabilitation
Pulmonary  rehabilitation  in  IPF  has  showed  an  improvement
in  walking  distance,  symptoms  and  HRQoL.  Although  the
long  term  beneﬁt  of  rehabilitation  is  not  demonstrated,  it  is
recommended  for  the  majority  of  patients,  namely  in  early
stages  of  the  disease.1,82,83
Oxygen  therapy
Although  there  are  no  speciﬁc  data  concerning  the  use  of
long-term  oxygen  therapy  in  patients  with  IPF,  based  on
chronic  obstructive  pulmonary  disease  (COPD)  and  chronic
respiratory  failures  studies,  it  is  recommended  to  all  IPF
patients  with  resting  hypoxaemia.1
Lung  transplantIn  cases  that  meet  the  criteria,  lung  transplant  must  be
always  kept  in  mind  since  it  is,  according  to  the  interna-
tional  recommendations,  the  most  effective  and  reliable
treatment  for  patients  with  IPF.  Lung  transplantation  5-years
o
s
a
t119
urvival  rate  ranges  from  50%  to  56%  and  10-years  survival
ate  is  30%.1,84,85
reatment of complications and comorbidities
cute  exacerbation
igh-dose  corticosteroid  therapy  with  or  without  immuno-
uppressive  agents,  namely  cyclophosphamide,  and  wide
pectrum  antibiotics,  are  the  most  widely  used  treatments
or  the  acute  exacerbation  of  IPF  despite  the  lack  of  conclu-
ive  evidence  demonstrating  their  beneﬁts.1,86,87
astro-oesophageal  reﬂux
symptomatic  GER  is  common  in  IPF  and  may  impact  IPF
atural  history  and  progression.88 An  analysis  of  data  from
hree  randomized  controlled  trials  showed  that  IPF  patients
aking  proton  pump  inhibitors  (PPI)  and/or  H2  inhibitors  sig-
iﬁcantly  slower  decline  in  FVC  over  time.25 According  to  the
nternational  recommendations,  asymptomatic  GER  should
e  treated  in  the  majority  of  patients  with  IPF,  namely  with
PI.1,53
ulmonary  hypertension
n  two  uncontrolled  prospective  studies  of  sildenaﬁl  in
atients  with  pulmonary  hypertension  in  context  of  IPF,  walk
istance  and  pulmonary  haemodynamics  improved  after
--12  weeks  of  treatment.89,90 In  the  randomized  controlled
TEP-IPF  (Sildenaﬁl  Trial  of  Exercise  Performance  in  IPF)
rial,  comparing  20  mg  tid  of  sildenaﬁl  and  placebo  over  12
eeks,  no  signiﬁcant  improvement  of  the  6MWT  (primary
nd-point)  was  observed;  however  arterial  oxygenation,  dif-
using  capacity  of  the  lung  for  carbon  monoxide  (DLCO),
yspnoea  and  quality  of  life  were  improved  in  patients  on
ildenaﬁl.80
However,  in  a  subgroup  analysis  of  patients  with
ight  ventricular  systolic  dysfunction  echocardiogram-
ocumented,  sildenaﬁl  treatment  resulted  in  a  signiﬁcant
mprovement  in  the  primary  outcome  of  6MWT  (mean
istance,  99.3  m;  95%  CI  22.3--176.2  m).91 Considering
hese  results,  although  without  a  clear  recommenda-
ion,  sildenaﬁl  can  be  one  option  in  patients  with
PF  and  pulmonary  hypertension  with  right  ventricular
ysfunction.
Due  to  lack  of  evidence,  any  drug  from  prostacycline
nalogues  or  endothelin  receptor  antagonists  (ERA)  are  not
ndicated  for  use  in  IPF.52 Moreover,  ambrisentan,  an  ERA,
s  contraindicated  in  IPF,  since  the  ARTEMIS-IPF  randomized
ontrolled  trial  showed  an  increase  number  of  hospitaliza-
ions  for  respiratory  complications.92
alliative care
he  aim  of  palliative  care  is  to  improve  patients’  quality
f  life.  It  is  important  to  take  into  account  not  only  the
ymptoms  related  with  the  disease  progression,  like  cough
nd  dyspnoea,  where  codeine  and  morphine  have  shown
o  be  effective,  but  also  psychological  aspects  inherent  to
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220  
hose  who  face  this  poor  prognostic  and  great  disabling
isease.1,93--95
onclusions
o  change  the  scenario  of  this  devastating  disease,  early
dentiﬁcation  and  referral  of  IPF  patients  to  a  specialized
entre  is  needed.  Training  of  General  Practitioners  and  fur-
her  awareness  of  pulmonologists  not  specialized  in  IPF  is
ssential  to  achieve  this.
Every  patient  older  than  50  years  of  age,  with  exertional
yspnoea  and  dry,  non-productive  cough,  with  ongoing  or
revious  smoking  habits  and  bi-basal  crackles  on  ausculta-
ion,  should  have  rapid  access  to  a  multidisciplinary  team.
This  multidisciplinary  approach  demands  the  judicious
se,  not  only  of  HRCT  information  and  histopathology  when
eeded,  but  also  of  all  non-standardized  data  available  in
ndividual  patients,  such  as  BAL,  serology  tests  and  biomark-
rs.
Unfortunately  speciﬁc  biomarkers  are  yet  to  be  found  and
ess  invasive  methods  to  reach  lung  tissue  are  far  from  being
stablished.
Nevertheless  recent  advances  in  clinical  research  allowed
he  release  of  new  and  promising  molecules,  nintedanib
nd  pirfenidone,  two  antiﬁbrotic  drugs  with  diverse  mecha-
isms  of  action  that  presented  efﬁcacy  in  slowing  functional
ecline  and  disease  progression  in  IPF  patients.
Finally  it  must  be  stressed  that  in  IPF  the  therapeutic
trategy  should  be  individualized  to  each  patient,  consider-
ng,  not  only  the  evaluation  of  potential  beneﬁts  and  risks,
ut  also  and  most  importantly,  taking  into  account  the  clin-
cal  behaviour  of  the  disease.
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